Successful rescue therapy with darunabir (TMC114) in HIV-infected patients who have failed several ritonavir-boosted protease inhibitors

被引：19

作者：

Poveda, Eva ^{[1
]}

Blanco, Francisco ^{[1
]}

Garcia-Gasco, Pilar ^{[1
]}

Alcolea, Antonio ^{[1
]}

Briz, Veronica ^{[1
]}

Soriano, Vincent ^{[1
]}

机构：

[1] Univ Carlos III Madrid, Dept Infect Dis, Madrid, Spain

来源：

AIDS | 2006年 / 20卷 / 11期

关键词：

D O I：

10.1097/01.aids.0000237375.23692.f4

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Darunabir, formerly TMC114, is a new protease inhibitor (PI) under clinical development designed to be active against HIV strains resistant to currently available PI. The virological and immunological response to ritonavir-boosted darunabir was assessed in four heavily antiretroviral-experienced patients who had failed enfuvirtide and two or more previous ritonavir-boosted PI regimens, including tipranavir in one instance. All four patients reached undetectable plasma HIV-RNA levels within 8 weeks of therapy and experienced significant CD4 cell count gains.

引用

页码：1558 / 1560

页数：3

共 11 条

[1] Comparison of the efficacy, safety and predictive value of HIV genotyping using distinct ritonavir-boosted protease inhibitors [J].

Barreiro, P ;

Camino, N ;

de Mendoza, C ;

Valer, L ;

Núñez, M ;

Martín-Carbonero, L ;

González-Lahoz, J ;

Soriano, V .

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2002, 20 (06) :438-443

[2] TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates [J].

De Meyer, S ;

Azijn, H ;

Surleraux, D ;

Jochmans, D ;

Tahri, A ;

Pauwels, R ;

Wigerinck, P ;

de Béthune, MP .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (06) :2314-2321

[3]

DEMEYER S, 2006, 13 C RETR OP INF CRO

[4] Rate of virological treatment failure and frequencies of drug resistance genotypes among human immunodeficiency virus-positive subjects on antiretroviral therapy in Spain [J].

Gallego, O ;

Ruíz, L ;

Vallejo, A ;

Clotet, B ;

Leal, M ;

Soriano, V .

JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (10) :3865-3866

[5] World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing [J].

Harrigan, PR ;

Montaner, JSG ;

Wegner, SA ;

Verbiest, W ;

Miller, V ;

Wood, R ;

Larder, BA .

AIDS, 2001, 15 (13) :1671-1677

[6]

Johnson Victoria A, 2005, Top HIV Med, V13, P125

[7] Baseline susceptibility of primary human immunodeficiency virus type 1 to entry inhibitors [J].

Labrosse, B ;

Labernardière, JL ;

Dam, E ;

Trouplin, V ;

Skrabal, K ;

Clavel, F ;

Mammano, F .

JOURNAL OF VIROLOGY, 2003, 77 (02) :1610-1613

[8] Human immunodeficiency virus type 1 genotypic and pharmacokinetic, determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients [J].

Masquelier, B ;

Breilh, D ;

Neau, D ;

Lawson-Ayayi, S ;

Lavignolle, V ;

Ragnaud, JM ;

Dupon, M ;

Morlat, P ;

Dabis, F ;

Fleury, H .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (09) :2926-2932

[9] A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1 [J].

Petropoulos, CJ ;

Parkin, NT ;

Limoli, KL ;

Lie, YS ;

Wrin, T ;

Huang, W ;

Tian, H ;

Smith, D ;

Winslow, GA ;

Capon, DJ ;

Whitcomb, JM .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (04) :920-928

[10] Dynamics of enfuvirtide resistance in HIV-infected patients during and after long-term enfuvirtide salvage therapy [J].

Poveda, E ;

Rodés, B ;

Lebel-Binay, S ;

Faudon, JL ;

Jimenez, V ;

Soriano, V .

JOURNAL OF CLINICAL VIROLOGY, 2005, 34 (04) :295-301

← 1 2 →